ACAD
34.98
0.00
0.00%
AEMD
5.11
+0.33
+6.90%
APRI
0.35
-0.048
-12.0694%
ARNA
1.74
-0.03
-1.69%
ATEC
8.63
+0.38
+4.61%
CNAT
2.11
-0.05
-2.31%
CRXM
0.27
0.00
+0.15%
CYTX
2.12
+0.03
+1.44%
DXCM
93.91
-0.11
-0.12%
GNMK
11.7
-0.08
-0.68%
HALO
12.09
-0.31
-2.50%
ILMN
179.33
-0.01
-0.01%
INNV
0.28
-0.01
-3.78%
INO
9.5
-0.24
-2.46%
ISCO
1.9
+0.1
+5.56%
ISIS
57.56
0.00
0.00%
LGND
115.78
-2.38
-2.01%
LPTN
3.89
+0.29
+8.06%
MBVX
4.72
-0.04
-0.84%
MEIP
1.69
-0.04
-2.31%
MNOV
7.1
+0.03
+0.42%
MRTX
5.88
-0.58
-8.98%
MSTX
0.127
-0.006
-4.2825%
NBIX
53.94
-0.22
-0.41%
NUVA
66.77
-1.29
-1.90%
ONCS
1.78
+0.01
+0.56%
ONVO
3.97
-0.03
-0.75%
OREX
3.46
+0.01
+0.29%
OTIC
17.65
-0.74
-4.02%
QDEL
22.71
-0.08
-0.35%
RCPT
231.96
0.00
0.00%
RGLS
3.45
+0.03
+0.88%
RMD
63.25
-0.73
-1.14%
SPHS
2.96
0.00
0.00%
SRNE
7.77
-0.1
-1.27%
TROV
4.79
+0.02
+0.42%
VICL
3.25
+0.06
+1.88%
VOLC
18
0.00
0.00%
ZGNX
10.45
+0.93
+9.77%
ACAD
34.98
0.00
0.00%
AEMD
5.11
+0.33
+6.90%
APRI
0.35
-0.048
-12.0694%
ARNA
1.74
-0.03
-1.69%
ATEC
8.63
+0.38
+4.61%
CNAT
2.11
-0.05
-2.31%
CRXM
0.27
0.00
+0.15%
CYTX
2.12
+0.03
+1.44%
DXCM
93.91
-0.11
-0.12%
GNMK
11.7
-0.08
-0.68%
HALO
12.09
-0.31
-2.50%
ILMN
179.33
-0.01
-0.01%
INNV
0.28
-0.01
-3.78%
INO
9.5
-0.24
-2.46%
ISCO
1.9
+0.1
+5.56%
ISIS
57.56
0.00
0.00%
LGND
115.78
-2.38
-2.01%
LPTN
3.89
+0.29
+8.06%
MBVX
4.72
-0.04
-0.84%
MEIP
1.69
-0.04
-2.31%
MNOV
7.1
+0.03
+0.42%
MRTX
5.88
-0.58
-8.98%
MSTX
0.127
-0.006
-4.2825%
NBIX
53.94
-0.22
-0.41%
NUVA
66.77
-1.29
-1.90%
ONCS
1.78
+0.01
+0.56%
ONVO
3.97
-0.03
-0.75%
OREX
3.46
+0.01
+0.29%
OTIC
17.65
-0.74
-4.02%
QDEL
22.71
-0.08
-0.35%
RCPT
231.96
0.00
0.00%
RGLS
3.45
+0.03
+0.88%
RMD
63.25
-0.73
-1.14%
SPHS
2.96
0.00
0.00%
SRNE
7.77
-0.1
-1.27%
TROV
4.79
+0.02
+0.42%
VICL
3.25
+0.06
+1.88%
VOLC
18
0.00
0.00%
ZGNX
10.45
+0.93
+9.77%
Home » Archive by Category

Xconomy

Retrophin Drug Licensed by Shkreli Shows Positive Phase 2 Results

September 7, 2016 – 2:52 pm

Retrophin, the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. San…

[[Click headline to continue reading.]]

Immunotherapy Clinical Tests Spur Hope, and Plenty of Headaches

September 7, 2016 – 3:30 am

Thanks to remarkable results in a small group of patients, including former U.S. President Jimmy Carter, cancer immunotherapy has spurred talk of once impossible-to-imagine cures and has gained its…

[[Click headline to continue reading.]]

Bio Roundup: RIP Roger Tsien, Novartis CAR-T Wheel, Zika News & More

September 2, 2016 – 3:19 am

A man who helped shed light—fluorescent light—on biology died far too early, at the age of 64. Nobel Prize winner Roger Tsien, a UC San Diego chemist, passed away in Oregon this week. No…

[[Click headline to continue reading.]]

UC San Diego Nobel Laureate Roger Tsien Dies at 64

August 31, 2016 – 9:38 pm

Roger Tsien, a UC San Diego scientist who shared the 2008 Nobel Prize in chemistry for research that led to the development of fluorescent proteins used to illuminate tissue and track biological…

[[Click headline to continue reading.]]

Synthetic Genomics Creates Host Organism Optimized for Bio Industry

August 29, 2016 – 8:00 am

Scientists from Synthetic Genomics, the San Diego-based industrial biotech, have re-engineered a fast-growing microorganism found in salt marsh mud to maximize its production of proteins and to…

[[Click headline to continue reading.]]

The XX Factor: Fixing Biotech’s Gender Imbalance in the C-Suite

August 29, 2016 – 12:00 am

Women continue to be vastly under-represented in management and executive-level positions throughout the life science industry—an inequity that came into the spotlight earlier this year when a…

[[Click headline to continue reading.]]

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

August 26, 2016 – 4:55 am

It was the tweet heard around the biotech world, again. Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes,…

[[Click headline to continue reading.]]

Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA

August 26, 2016 – 3:40 am

[Updated, 1:09 pm ET, see below] Heather and Jessica Tomko will tell you that they’re nothing alike. They’ve got different interests, different tastes in movies, television, and music. If Jessica…

[[Click headline to continue reading.]]

Who’s to Blame for Inflated Health Insurance Costs?

August 24, 2016 – 8:51 am

How often would you go to the doctor if you had to pay for a big chunk out of pocket—or how about if it was completely free? The amount of health care we consume depends on how good our health…

[[Click headline to continue reading.]]

In Wake Of Infamous Biotech Party, 20 Women Join New Exec Training

August 23, 2016 – 3:34 pm

[Updated 8/24/16, 1 a.m. See below.] A new program to prepare high-ranking women in the biotech industry for corporate board seats has unveiled its first class of 20. In other circumstances the…

[[Click headline to continue reading.]]